Current Neuropharmacology

T.E. Salt
University College London
Institute of Ophthalmology
London EC1V 9EL
UK

Back

Parkinsons Disease: Genetics and Beyond

Author(s): N. N. Inamdar, D. K. Arulmozhi, A. Tandon and S. L. Bodhankar

Affiliation: Department of Pharmacology,Bharati Vidyapeeth University, Poona College of Pharmacy, Erandwane,Pune 411 038, India.

Abstract:

Parkinsons disease (PD) is characterized clinically by resting tremor, rigidity, bradykinesia and postural instability due to progressive and selective loss of dopamine neurons in the ventral substantia nigra, with the presence of ubiquitinated protein deposits called Lewy bodies in the neurons. The pathoetiology of cell death in PD is incompletely understood and evidence implicates impaired mitochondrial complex I function, altered intracellular redox state, activation of proapoptotic factors and dysfunction of ubiquitinproteasome pathway. Now it is believed that genetic aberration, an environmental toxin or combination of both leads to a cascade of events culminating in the destruction of myelinated brainstem catecholaminergic neurons. Also the role of production of significant levels of abnormal proteins, which may misfold, aggregate and interfere with intracellular processes causing cytotoxicity has recently been hypothesized. In this article, the diverse pieces of evidence that have linked the various factors responsible for the pathophysiology of PD are reviewed with special emphasis to various candidate genes and proteins. Furthermore, the present therapeutic strategies and futuristic approaches for the pharmacotherapy of PD are critically discussed.

Keywords: Parkinson's disease., lewy bodies, protein aggregation, pathophysiology, α-Synuclein, Parkin, Mitochondrial dysfunction

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 5
ISSUE: 2
Page: [99 - 113]
Pages: 15
DOI: 10.2174/157015907780866893
Price: $58